CMV 糖蛋白 B 疫苗联合 MF59 佐剂的研发与疗效证据。
Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant.
机构信息
Department of Pediatrics, University of Alabama at Birmingham, USA.
出版信息
J Clin Virol. 2009 Dec;46 Suppl 4(Suppl 4):S73-6. doi: 10.1016/j.jcv.2009.07.002. Epub 2009 Jul 31.
Abstract
A vaccine comprised of recombinant cytomegalovirus (CMV) envelope glycoprotein B (gB) with MF59 adjuvant developed in the 1990s recently was recently found to have efficacy for prevention of CMV infection in a phase 2 clinical trial in young mothers. This review briefly considers the rationale for gB as a vaccine antigen, the history of this CMV gB vaccine and the data supporting vaccine efficacy.
摘要
一种由重组巨细胞病毒（CMV）包膜糖蛋白 B（gB）与 MF59 佐剂组成的疫苗，于 20 世纪 90 年代开发成功，最近在一项针对年轻母亲的 2 期临床试验中发现对预防 CMV 感染有效。这篇综述简要讨论了 gB 作为疫苗抗原的原理、这种 CMV gB 疫苗的历史以及支持疫苗有效性的数据。
相似文献
1
Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant.CMV 糖蛋白 B 疫苗联合 MF59 佐剂的研发与疗效证据。
J Clin Virol. 2009 Dec;46 Suppl 4(Suppl 4):S73-6. doi: 10.1016/j.jcv.2009.07.002. Epub 2009 Jul 31.
2
Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.巨细胞病毒糖蛋白B（gB）疫苗在青春期女孩中的安全性和有效性：一项随机临床试验。
Vaccine. 2016 Jan 12;34(3):313-9. doi: 10.1016/j.vaccine.2015.11.056. Epub 2015 Dec 2.
3
Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.在健康的巨细胞病毒血清阴性成年人中，先前或同时接种表达巨细胞病毒（CMV）糖蛋白B（gB）的金丝雀痘病毒对亚单位gB疫苗加MF59免疫反应的影响。
J Infect Dis. 2002 Mar 1;185(5):686-90. doi: 10.1086/339003. Epub 2002 Feb 6.
4
Vaccines for cytomegalovirus.巨细胞病毒疫苗
Infect Disord Drug Targets. 2011 Oct;11(5):514-25. doi: 10.2174/187152611797636695.
5
Avidity maturation following immunization with two human cytomegalovirus (CMV) vaccines: a live attenuated vaccine (Towne) and a recombinant glycoprotein vaccine (gB/MF59).接种两种人巨细胞病毒（CMV）疫苗后的亲和力成熟：一种减毒活疫苗（汤氏株）和一种重组糖蛋白疫苗（gB/MF59）。
Viral Immunol. 2003;16(4):491-500. doi: 10.1089/088282403771926319.
6
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial.用 MF59 佐剂的巨细胞病毒糖蛋白 B 疫苗在移植受者中的效果：一项 2 期随机安慰剂对照试验。
Lancet. 2011 Apr 9;377(9773):1256-63. doi: 10.1016/S0140-6736(11)60136-0.
7
Vaccine prevention of maternal cytomegalovirus infection.疫苗预防孕妇巨细胞病毒感染。
N Engl J Med. 2009 Mar 19;360(12):1191-9. doi: 10.1056/NEJMoa0804749.
8
Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine.人巨细胞病毒 mRNA-1647 疫苗候选物比 gB/MF59 疫苗诱导更强和更广泛的中和及抗体依赖性细胞细胞毒性反应。
J Infect Dis. 2024 Aug 16;230(2):455-466. doi: 10.1093/infdis/jiad593.
9
Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers.重组人巨细胞病毒gB疫苗在血清学阴性幼儿中的免疫原性。
Pediatr Infect Dis J. 2002 Feb;21(2):133-8. doi: 10.1097/00006454-200202000-00009.
引用本文的文献
1
Selective knockout of key CMV receptors in fetal cells blocks direct and endocytic pathways of entry in the guinea pig.在胎儿细胞中选择性敲除关键巨细胞病毒（CMV）受体可阻断豚鼠的直接和内吞进入途径。
bioRxiv. 2025 Aug 5:2025.08.05.668711. doi: 10.1101/2025.08.05.668711.
2
Complete cross strain protection against congenital cytomegalovirus infection requires a vaccine encoding key antibody (gB) and T-cell (immediate early 1 protein) viral antigens.针对先天性巨细胞病毒感染实现完全的交叉毒株保护需要一种编码关键抗体（gB）和T细胞（即刻早期1蛋白）病毒抗原的疫苗。
bioRxiv. 2025 Jun 20:2025.06.18.660432. doi: 10.1101/2025.06.18.660432.
3
Human cytomegalovirus gH/gL/gO binding to PDGFRα provides a regulatory signal activating the fusion protein gB that can be blocked by neutralizing antibodies.人巨细胞病毒gH/gL/gO与血小板衍生生长因子受体α（PDGFRα）的结合提供了一种调节信号，可激活融合蛋白gB，而该信号可被中和抗体阻断。
J Virol. 2025 May 20;99(5):e0003525. doi: 10.1128/jvi.00035-25. Epub 2025 Apr 9.
4
The pentameric complex is not required for congenital CMV transmission in seronegative rhesus macaques.对于血清阴性的恒河猴而言，先天性巨细胞病毒传播并不需要五聚体复合物。
Sci Transl Med. 2025 Mar 12;17(789):eadm8961. doi: 10.1126/scitranslmed.adm8961.
5
Human cytomegalovirus gH/gL/gO binding to PDGFRα provides a regulatory signal activating the fusion protein gB that can be blocked by neutralizing antibodies.人巨细胞病毒gH/gL/gO与血小板衍生生长因子受体α（PDGFRα）结合可提供一种调节信号，激活融合蛋白gB，而该信号可被中和抗体阻断。
bioRxiv. 2025 Jan 8:2025.01.08.631902. doi: 10.1101/2025.01.08.631902.
6
T cell inducing vaccine against cytomegalovirus immediate early 1 (IE1) protein provides high level cross strain protection against congenital CMV.针对巨细胞病毒即刻早期1（IE1）蛋白的T细胞诱导疫苗可提供高水平的针对先天性巨细胞病毒的交叉株保护。
Vaccine. 2024 Dec 2;42(26):126357. doi: 10.1016/j.vaccine.2024.126357. Epub 2024 Sep 18.
7
Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth.多价巨细胞病毒糖蛋白B核苷修饰mRNA疫苗并未显示出更广泛的抗体谱。
NPJ Vaccines. 2024 Feb 20;9(1):38. doi: 10.1038/s41541-024-00821-3.
8
Vaccination with a replication-defective cytomegalovirus vaccine elicits a glycoprotein B-specific monoclonal antibody repertoire distinct from natural infection.接种复制缺陷型巨细胞病毒疫苗所引发的糖蛋白B特异性单克隆抗体库不同于自然感染所引发的抗体库。
NPJ Vaccines. 2023 Oct 10;8(1):154. doi: 10.1038/s41541-023-00749-0.
9
A temperature-dependent virus-binding assay reveals the presence of neutralizing antibodies in human cytomegalovirus gB vaccine recipients' sera.一种依赖温度的病毒结合测定法揭示了人巨细胞病毒 gB 疫苗接种者血清中存在中和抗体。
J Gen Virol. 2023 Jun;104(6). doi: 10.1099/jgv.0.001860.
10
Endothelial Cell Infection by Guinea Pig Cytomegalovirus Is a Lytic or Persistent Infection Depending on Tissue Origin but Requires Viral Pentamer Complex and pp65 Tegument Protein.豚鼠巨细胞病毒感染血管内皮细胞取决于组织来源，为裂解性或持续性感染，但需要病毒五聚体复合物和 pp65 被膜蛋白。
J Virol. 2022 Sep 14;96(17):e0083122. doi: 10.1128/jvi.00831-22. Epub 2022 Aug 24.
本文引用的文献
1
Vaccine prevention of maternal cytomegalovirus infection.疫苗预防孕妇巨细胞病毒感染。
N Engl J Med. 2009 Mar 19;360(12):1191-9. doi: 10.1056/NEJMoa0804749.
2
Safety of MF59 adjuvant.MF59佐剂的安全性。
Vaccine. 2008 Jun 19;26(26):3209-22. doi: 10.1016/j.vaccine.2008.03.093. Epub 2008 Apr 21.
3
Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.一种二价巨细胞病毒DNA疫苗在健康成年受试者中的安全性和免疫原性。
J Infect Dis. 2008 Jun 15;197(12):1634-42. doi: 10.1086/588385.
4
Comparison of vaccine strategies against congenital CMV infection in the guinea pig model.豚鼠模型中针对先天性巨细胞病毒感染的疫苗策略比较。
J Clin Virol. 2008 Mar;41(3):224-30. doi: 10.1016/j.jcv.2007.10.008. Epub 2007 Dec 3.
5
A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.4种活性重组人巨细胞病毒Towne/Toledo嵌合疫苗的1期研究。
J Infect Dis. 2006 May 15;193(10):1350-60. doi: 10.1086/503365. Epub 2006 Apr 12.
6
Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding.在健康年轻女性疫苗临床试验期间对巨细胞病毒感染的检测：血清转化和病毒脱落
J Clin Virol. 2006 Mar;35(3):338-42. doi: 10.1016/j.jcv.2005.09.020. Epub 2006 Jan 4.
7
Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine.糖蛋白B疫苗临床试验期间巨细胞病毒感染的检测
Vaccine. 2004 Dec 9;23(4):507-10. doi: 10.1016/j.vaccine.2004.06.027.
8
Interval between births and risk of congenital cytomegalovirus infection.出生间隔与先天性巨细胞病毒感染风险
Clin Infect Dis. 2004 Apr 1;38(7):1035-7. doi: 10.1086/382533. Epub 2004 Mar 15.
9
Maternal immunity and prevention of congenital cytomegalovirus infection.母体免疫与先天性巨细胞病毒感染的预防
JAMA. 2003 Feb 26;289(8):1008-11. doi: 10.1001/jama.289.8.1008.
10
Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.在健康的巨细胞病毒血清阴性成年人中，先前或同时接种表达巨细胞病毒（CMV）糖蛋白B（gB）的金丝雀痘病毒对亚单位gB疫苗加MF59免疫反应的影响。
J Infect Dis. 2002 Mar 1;185(5):686-90. doi: 10.1086/339003. Epub 2002 Feb 6.
Zotero 插件